Classical pathology and mutational load of breast cancer – integration of two worlds

Journal of Pathology: Clinical Research

Volumn 2, Issue 1, 2016, Pages 225-238

  Budczies, Jan ^a,b   Bockmayr, Michael ^a   Denkert, Carsten ^a,b   Klauschen, Frederick ^a   Lennerz, Jochen K ^c   Györffy, Balázs ^d,e   Dietel, Manfred ^a,b   Loibl, Sibylle ^f   Weichert, Wilko ^b,g   Stenzinger, Albrecht ^g,h  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^e SEMMELWEIS UNIVERSITY   (Hungary)

^f German Breast Group   (Germany)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^h National Center of Tumor Diseases Heidelberg School of Oncology (NCT HSO)   (Germany)

Author keywords

breast cancer; clinical parameters; genetics; mutations; pathology; prognosis; staging; tumour grade; tumour size

Indexed keywords

EID: 85056746747     PISSN: None     EISSN: 20564538     Source Type: Journal    
DOI: 10.1002/cjp2.25     Document Type: Article

References (57)

1. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012; 486: 400–404.
2. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61–70.
3. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014; 64: 52–62
4. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747–752.
5. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869–10874.
6. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100: 8418–8423.
7. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10: R65.
8. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011; 378: 1812–1823.
9. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486: 346–352.
10. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999–2009.
11. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817–2826.
12. Kronenwett R, Bohmann K, Prinzler J, Sinn BV, Haufe F, Roth C, et al. Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test. BMC Cancer 2012; 12: 456.
13. Viale G. The current state of breast cancer classification. Ann Oncol 2012; 23(Suppl 10): x207–10.
14. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002; 20: 3628–3636.
15. Mittendorf EA, Jeruss JS, Tucker SL, Kolli A, Newman LA, Gonzalez-Angulo AM, et al. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 2011; 29: 1956–1962.
16. Bagaria SP, Ray PS, Sim MS, Ye X, Shamonki JM, Cui X, et al. Personalizing breast cancer staging by the inclusion of ER, PR, and HER2. JAMA Surg 2014; 149: 125–129.
17. Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 1992; 20: 479–489.
18. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403–410.
19. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359–377.
20. Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 2010; 12: 207.
21. Goldhirsch, A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736–1747.
22. Rakha EA, Ellis IO. Modern classification of breast cancer: should we stick with morphology or convert to molecular profile characteristics. Adv Anat Pathol 2011; 18: 255–267.
23. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98: 262–272.
24. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009; 461: 809–813.
25. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486: 395–399.
26. Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 2014; 512: 155–160.
27. Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H, et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 2014; 518: 422–426.
28. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, et al. Breast cancer working group of the international cancer genome consortium. Mutational processes molding the genomes of 21 breast cancers. Cell 2012; 149: 979–993.
29. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, et al. Breast cancer working group of the international cancer genome consortium. The life history of 21 breast cancers. Cell 2012; 149: 994–1007.
30. Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, et al. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep 2014; 6: 514–527.
31. Almendro V, Kim HJ, Cheng YK, Gönen M, Itzkovitz S, Argani P, et al. Genetic and phenotypic diversity in breast tumor metastases. Cancer Res 2014; 74: 1338–1348.
32. Campbell LL, Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle 2007; 6: 2332–2338.
33. Martelotto LG, Ng CK, Piscuoglio S, Weigelt B, Reis-Filho JS, et al. Breast cancer intra-tumor heterogeneity. Breast Cancer Res 2014; 16: R48.
34. Burrell RA, McGranahan N, Bartek J, Swanton C, et al. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013; 501: 338–345.
35. R Development Core Team. 2014. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available at: http://www.R-project.org/. last accessed on May 20, 2015.
36. Seshan VE. 2014. Clinfun: clinical trial design and data analysis functions. R package version 1.0.6. Available at: http://CRAN.R-project.org/package=clinfun. last accessed on May 20, 2015.
37. Eklund A. 2013. Beeswarm: the bee swarm plot, an alternative to stripchart. R package version 0.1.6. Available at: http://CRAN.R-project.org/package=beeswarm. last accessed on May 20, 2015.
38. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. Springer: New York, 2000; ISBN 0-387-98784-3.
39. Dorai-Raj S. 2014. Binom: binomial confidence intervals for several parameterizations. R package version 1.1-1. Available at: http://CRAN.R-project.org/package=binom. last accessed on May 20, 2015.
40. Venables WN, Ripley BD. Modern Applied Statistics with S (4th edn). Springer: New York, 2002; ISBN 0–387-95457-0.
41. Powell JA. GO2MSIG, an automated GO based multi-species gene set generator for gene set enrichment analysis. BMC Bioinformatics 2014; 15: 146.
42. Budczies J, Klauschen F, Sinn BV, Györffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff Finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS One. 2012; 7: e51862.
43. Cornejo KM, Kandil D, Khan A, Cosar EF, et al. Theranostic and molecular classification of breast cancer. Arch Pathol Lab Med 2014; 138: 44–56
44. Bertucci F, Orsetti B, Nègre V, Finetti P, Rougé C, Ahomadegbe JC, et al. Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene 2008; 27: 5359–5372.
45. Petridis C, Shinomiya I, Kohut K, Gorman P, Caneppele M, Shah V, et al. Germline CDH1 mutations in bilateral lobular carcinoma in situ. Br J Cancer 2014; 110: 1053–1057.
46. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability—an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010; 11: 220–228.
47. Hernando E, Nahle Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M, et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 2004; 430: 797–802.
48. Bhaskara S, Knutson SK, Jiang G, Chandrasekharan MB, Wilson AJ, Zheng S, et al. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell 2010; 18: 436–447.
49. Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci USA 2009; 106: 9435–9440.
50. Meehan M, Parthasarathi L, Moran N, Jefferies CA, Foley N, Lazzari E, et al. Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene. Mol Cancer 2012; 11: 6.
51. Ertych N, Stolz A, Stenzinger A, Weichert W, Kaulfuβ S, Burfeind P, et al. Increased microtubule assembly rates influence chromosomal instability in colorectal cancer cells. Nat Cell Biol 2014; 16: 779–791.
52. Wallace MD, Pfefferle AD, Shen L, McNairn AJ, Cerami EG, Fallon BL, et al. Comparative oncogenomics implicates the neurofibromin 1 gene (NF1) as a breast cancer driver. Genetics 2012; 192: 385–396.
53. Garza R, Hudson RA 3rd, McMahan CA, Walter CA, Vogel KS, et al. A mild mutator phenotype arises in a mouse model for malignancies associated with neurofibromatosis type 1. Mutat Res 2007; 615: 98–110.
54. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194: 23–28.
55. Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013; 31: 539–544.
56. Baccelli I, Stenzinger A, Vogel V, Pfitzner BM, Klein C, Wallwiener M, et al. Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients. Oncotarget 2014; 5: 8147–8160.
57. Budczies J, von Winterfeld M, Klauschen F, Bockmayr M, Lennerz JK, Denkert C, et al. The landscape of metastatic progression patterns across major human cancers. Oncotarget 2015; 6: 570–583.